Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients

医学 富维斯特朗 阿那曲唑 药代动力学 来曲唑 内科学 药效学 肿瘤科 中性粒细胞减少症 人口 非金属 药理学 芳香化酶抑制剂 相伴的 癌症 乳腺癌 芳香化酶 三苯氧胺 毒性 环境卫生
作者
Yasong Lu,Shu Yang,Yu‐Yun Ho,Yan Ji
出处
期刊:The Journal of Clinical Pharmacology [Wiley]
卷期号:61 (8): 1054-1068 被引量:30
标识
DOI:10.1002/jcph.1856
摘要

The population pharmacokinetics (popPK) of ribociclib and population pharmacokinetic/pharmacodynamic (PK/PD) relationship between ribociclib and absolute neutrophil count (ANC) were characterized in patients with cancer. PopPK and ANC PK/PD modeling were both conducted in 2 rounds per data availability. Initial models were developed based on data sets from early-phase trials and qualified using external data from the phase III MONALEESA-2 trial. The second round of analyses was performed using updated data sets that included 2 more phase III trials (MONALEESA-3 and -7). The popPK and ANC PK/PD models adequately described the data and demonstrated reasonable predictive ability. Covariate analysis showed that ribociclib PK were not affected by age, sex, race, baseline Eastern Cooperative Oncology Group (ECOG) status (grade 1), mild/moderate renal impairment, mild hepatic impairment, or concomitant use of combination partners, including aromatase inhibitors (letrozole, anastrozole) or fulvestrant, proton-pump inhibitors, or weak cytochrome P450 3A4/5 inhibitors. Body weight had no impact on ribociclib clearance to warrant dose adjustment. The ANC PK/PD relationship was not affected by age, weight, sex, race, baseline ECOG status (grade 1), or concomitant use of letrozole, anastrozole, or fulvestrant. The PK/PD analysis confirmed reversibility of ribociclib's effect on ANC; it also suggested that lowering the dose of ribociclib would mitigate ANC decrease and neutropenia risk. The popPK and ANC PK/PD analyses support the use of ribociclib in combination with an aromatase inhibitor or fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced or metastatic breast cancer without dose adjustment in subpopulations, and the use of dose interruption/reduction to mitigate potential treatment-emergent neutropenia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
任伟超发布了新的文献求助10
1秒前
Lee发布了新的文献求助10
1秒前
千秋发布了新的文献求助20
1秒前
1秒前
2秒前
名字无法显示完成签到,获得积分10
3秒前
3秒前
纸飞机完成签到,获得积分10
3秒前
轻飏发布了新的文献求助10
4秒前
4秒前
科目三的应助被Hase采纳,获得10
4秒前
饼干不加酵母菌完成签到,获得积分10
5秒前
7秒前
yael完成签到,获得积分10
7秒前
李健的小迷弟的应助被渟柠采纳,获得10
7秒前
8秒前
zhilingZhang发布了新的文献求助10
8秒前
思源的应助被xhj采纳,获得10
10秒前
小蘑菇的应助被超级无敌采纳,获得30
10秒前
鱼游天下完成签到,获得积分10
10秒前
ecoochen发布了新的文献求助10
11秒前
脑洞疼的应助被adai采纳,获得10
11秒前
12秒前
英姑的应助被苹果依凝采纳,获得10
12秒前
上官若男的应助被Trick_Room采纳,获得10
13秒前
小牛发布了新的文献求助10
13秒前
深情安青的应助被闪闪严青采纳,获得10
15秒前
15秒前
烟花的应助被七颗茶香豆采纳,获得10
15秒前
15秒前
16秒前
bkagyin的应助被兴奋芝麻采纳,获得100
17秒前
秋风的应助被胡萝卜卜采纳,获得10
17秒前
派大星完成签到,获得积分10
17秒前
17秒前
DXL发布了新的文献求助10
17秒前
栖霜完成签到,获得积分20
17秒前
18秒前
18秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193348
求助须知:如何正确求助?哪些是违规求助? 9579548
关于积分的说明 21866040
捐赠科研通 7792906
什么是DOI,文献DOI怎么找? 3437242
关于科研通互助平台的介绍 2560702
邀请新用户注册赠送积分活动 2484066